核酸ベースの医薬品市場：薬物タイプ、分子タイプ、投与経路、治療領域、エンドユーザー別-2025-2030年世界予測

核酸ベースの医薬品市場は、2024年には333億7,000万米ドルとなり、2025年には377億6,000万米ドル、CAGR13.39%で成長し、2030年には709億5,000万米ドルに達すると予測されています。

核酸医薬品を取り巻く環境は、科学的な飛躍的進歩、革新的な臨床戦略、分子生物学への理解の深まりによって、過去10年間で大きく変化しました。この市場は、ニッチな研究分野から、複雑な疾患に対する治療的介入を再定義するダイナミックな分野へと変貌を遂げました。遺伝子発現調節における先駆的な発見は、RNAやDNAの機能性を標的とする薬剤など、さまざまなタイプの薬剤の発見と開発を形成し、これまでにない治療の可能性をもたらしています。新規の送達メカニズム、強化された合成技術、強固な規制上のサポートが統合されたことで、この分野は将来の治療法の礎石としてさらに確立されました。

バイオテクノロジーとデジタルの融合が進むことで、研究が加速するだけでなく、迅速な臨床応用への道も開かれています。学術界、製薬会社、臨床研究機関の利害関係者は、アンメット・メディカル・ニーズに対応するため、こうした開発を活用しています。画期的な科学と革新的な技術の融合により、この市場は患者の転帰と治療精度の大幅な向上を実現できる位置にあります。このように、核酸医薬品市場の継続的な進化は、急速に変化する世界な医療環境の中で課題を克服し、チャンスをつかむことのできる、強固で弾力的なエコシステムを反映しています。

核酸医薬品市場における変革的シフト

近年、核酸医薬品市場では、治療法や市場力学を再定義するような変革的な変化が起きています。臨床試験活動の急増は精密医療の重要性を浮き彫りにし、初期段階の化合物が臨床パイプラインをより迅速に進むことにつながっています。送達システムにおける画期的な技術革新は、核酸治療薬のバイオアベイラビリティとターゲティング効果を大幅に改善し、安定性と細胞への取り込みに関連する従来の課題を緩和しています。

ゲノム編集の進歩は、RNA生物学の理解向上と相まって、多用途で患者特異的な次世代治療の枠組みを提供しました。新たなビジネスモデルと協力的な枠組みにより、学術界、研究機関、産業界のリーダーが洞察とリソースを共有する、セクターを超えたパートナーシップが可能になりました。このような協力体制は、新薬候補を合理化された規制経路に統合し、迅速な市場参入を実現する上で不可欠です。

このようなシフトの影響は広範囲に及び、市場の成長を加速させるだけでなく、技術革新を促進する投資の波を刺激しています。強化された計算モデリングと最先端のバイオ製造技術により、利害関係者は現在、医薬品開発においてより高い柔軟性、設計精度、業務効率を享受しています。この市場における変革的なシフトは、継続的な改善と画期的な研究が長期的な成功の基盤となる環境を生み出しています。

戦略を推進する主要セグメント分析

核酸医薬品市場の多面的な性質は、根本的な動向に対する重要な洞察を提供する多様なセグメンテーション戦略によって浮き彫りにされています。薬剤の種類から見ると、市場はアンチセンス・オリゴヌクレオチド、DNA/RNAアプタマー、mRNAベースの治療薬、ヌクレオシド類似体、RNA干渉（RNAi）治療薬など、一連の治療様式を包含しています。特にRNAi治療薬については、マイクロRNA（MiRNA）、ショートヘアピンRNA（ShRNA）、ショート干渉RNA（SiRNA）に分類することで、より深く考察しています。

さらに、分子タイプに基づくセグメンテーションでは、市場を大型分子と小型分子に分け、各セグメントが独自の市場ダイナミクスと商業的可能性を示しています。投与経路のセグメンテーションは、患者のコンプライアンスと治療成績に関する貴重な洞察を提供し、その様式は吸入、筋肉内投与から静脈内投与、経口投与、皮下投与に及び、患者のニーズと臨床実践の複雑さを反映しています。

治療領域については、心血管疾患、感染症、代謝性疾患、神経疾患、腫瘍、希少疾患の各領域で市場を分析しています。感染症は細菌感染症、真菌感染症、ウイルス感染症に分類され、腫瘍は血液悪性腫瘍と固形腫瘍に分類されています。市場セグメンテーションは、学術・研究機関、契約研究機関、病院・調査機関、製薬・バイオテクノロジー企業への影響を評価します。この緻密なセグメンテーションは、戦略的な意思決定に役立つだけでなく、患者の人口統計、治療法の種類、地域差がどのように組み合わさって市場の軌道を形成しているのかについての詳細な見解も提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性疾患や慢性疾患の罹患率の上昇により、核酸ベースの医薬品の必要性が高まっています。
    • 核酸医薬品製造の促進に向けた政府投資の拡大
  • 抑制要因
    • 核酸ベースの医薬品に関連する高い製造コストと配合コスト
  • 機会
    • バイオテクノロジー企業間のパートナーシップと協力により、核酸ベースの医薬品を強化する
    • 核酸医薬品のバイオアベイラビリティを向上させる次世代デリバリーシステムの開発
  • 課題
    • 核酸ベースの医薬品の安全性と配信有効性に関する懸念
• 市場セグメンテーション分析
  • 薬剤の種類：ワクチン開発における変革的影響と重大な健康危機時の迅速な治療対応によるmRNAベースの治療薬の使用
  • 分子タイプ：製造、投与、費用対効果の面で有利な特性があるため、低分子医薬品が広く採用されている
  • 投与経路：ワクチン開発において重要な役割を果たすため、筋肉内注射が普及している
  • 治療領域：腫瘍学における核酸ベースの医薬品の活用
  • エンドユーザー：遺伝子制御と発現の複雑さを解明するための高度なツールの必要性から、学術機関や調査機関で広く使用されています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 核酸ベースの医薬品市場薬剤の種類別

• アンチセンスオリゴヌクレオチド
• DNA/RNAアプタマー
• mRNAベースの治療薬
• ヌクレオシド類似体
• RNA干渉（RNAi）治療薬
  • マイクロRNA（MiRNA）
  • ショートヘアピンRNA（ShRNA）
  • 短鎖干渉RNA（SiRNA）

第7章 核酸ベースの医薬品市場分子タイプ別

• 巨大分子
• 小分子

第8章 核酸ベースの医薬品市場：投与経路別

• 吸入
• 筋肉内
• 静脈内
• オーラル
• 皮下

第9章 核酸ベースの医薬品市場治療領域別

• 心血管疾患
• 感染症
  • 細菌感染症
  • 真菌感染症
  • ウイルス感染
• 代謝障害
• 神経疾患
• 腫瘍学
  • 造血悪性腫瘍
  • 固形腫瘍
• 希少疾患

第10章 核酸ベースの医薬品市場：エンドユーザー別

• 学術調査機関
• 契約調査機関
• 病院と診療所
• 製薬・バイオテクノロジー企業

第11章 南北アメリカの核酸ベースの医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の核酸ベースの医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの核酸ベースの医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alnylam Pharmaceuticals, Inc.
• Amgen Inc.
• Arcturus Therapeutics Holdings Inc.
• Arrowhead Pharmaceuticals, Inc.
• AstraZeneca PLC
• Beam Therapeutics Inc.
• Biogen, Inc.
• BioMarin Pharmaceutical Inc.
• BioNTech SE
• Bluebird Bio, Inc.
• CRISPR Therapeutics AG
• CureVac N.V.
• Dynavax Technologies Corporation
• Editas Medicine, Inc.
• Eli Lilly and Company
• Evotec SE
• F. Hoffmann-La Roche Ltd.
• Generation Bio Co.
• Gilead Sciences, Inc.
• GSK PLC
• Intellia Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Novartis AG
• Novo Nordisk A/S
• Orna Therapeutics, Inc.
• Pfizer Inc.
• ProQR Therapeutics N.V.
• Sangamo Therapeutics, Inc.
• Sanofi SA
• Sarepta Therapeutics, Inc.
• Silence Therapeutics PLC
• Stoke Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals Incorporated
• Voyager Therapeutics, Inc.
• Wave Life Sciences Ltd.

LIST OF FIGURES

• FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET MULTI-CURRENCY
• FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET MULTI-LANGUAGE
• FIGURE 3. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
• FIGURE 4. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 114. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 117. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 118. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 125. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 126. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 149. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 157. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 158. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 165. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 166. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 181. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 182. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 189. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 190. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 197. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 198. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 199. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 214. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 215. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 220. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 222. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 223. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 224. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 230. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 231. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 232. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 237. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 238. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 239. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 244. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 246. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 247. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 248. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 252. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 253. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 254. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 255. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 256. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 257. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 258. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 259. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 260. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 261. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 262. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 263. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 268. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 270. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 271. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 272. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 276. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 278. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 279. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 280. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 284. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 285. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 286. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 287. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 289. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 290. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 291. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 292. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 293. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 294. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 295. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 296. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 297. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 298. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 299. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 300. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 301. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 302. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 303. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 304. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 308. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 309. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 310. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 311. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 312. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 316. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2

The Nucleic Acid-Based Drugs Market was valued at USD 33.37 billion in 2024 and is projected to grow to USD 37.76 billion in 2025, with a CAGR of 13.39%, reaching USD 70.95 billion by 2030.

The landscape of nucleic acid-based drugs has evolved substantially over the past decade, driven by significant scientific breakthroughs, innovative clinical strategies, and a deepening understanding of molecular biology. This market has transformed from a niche area of research to a dynamic field that is redefining therapeutic interventions for complex diseases. Pioneering discoveries in gene expression modulation have shaped the discovery and development of various drug types, such as those that target RNA and DNA functionality, leading to unprecedented therapeutic possibilities. The integration of novel delivery mechanisms, enhanced synthesis techniques, and robust regulatory support has further established this sector as a cornerstone for future medical treatments.

The ongoing convergence of biotechnology and digital advancements has not only accelerated research but has also paved the way for rapid clinical translations. Stakeholders across academia, pharmaceutical companies, and clinical research institutes are leveraging these developments to address unmet medical needs. This blend of breakthrough science and innovative technology positions the market to deliver substantial improvements in patient outcomes and therapeutic precision. As such, the ongoing evolution of the nucleic acid-based drugs market reflects a robust and resilient ecosystem capable of surmounting challenges and seizing opportunities in a rapidly changing global healthcare environment.

Transformative Shifts in the Nucleic Acid-Based Drugs Market

Recent years have witnessed transformative shifts in the nucleic acid-based drugs market that are redefining therapeutic modalities and market dynamics. A surge in clinical trial activity has underscored the importance of precision medicine, leading to early-stage compounds progressing more rapidly through clinical pipelines. Breakthrough innovations in delivery systems have significantly improved the bioavailability and targeting efficacy of nucleic acid therapeutics, thereby mitigating traditional challenges associated with stability and cellular uptake.

Advances in genomic editing, coupled with an enhanced understanding of RNA biology, have provided the framework for next-generation treatments that are both versatile and patient-specific. Emerging business models and collaborative frameworks have enabled cross-sector partnerships, where academia, research organizations, and industry leaders share insights and resources. This collaborative spirit has been essential in integrating novel drug candidates into streamlined regulatory pathways and expedited market accesses.

The impact of these shifts is far-reaching, inspiring a wave of investments that not only accelerate market growth but also foster technological innovation. With enhanced computational modeling and state-of-the-art biomanufacturing techniques, stakeholders now enjoy greater flexibility, design precision, and operational efficiency in drug development. The transformative shifts in this market are creating an environment where continuous improvement and breakthrough research are the foundations for long-term success.

Key Segmentation Insights Driving Strategy

The multifaceted nature of the nucleic acid-based drugs market is highlighted by a diverse segmentation strategy that provides critical insights into underlying trends. From a drug type perspective, the market encompasses an array of therapeutic modalities including Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. In particular, RNAi Therapeutics are examined in greater depth by further classifying the category into MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA), each with distinctive mechanisms of action that pave the way for targeted therapy solutions.

In addition, the segmentation based on molecule type divides the market into Large Molecules and Small Molecules, with each segment demonstrating unique market dynamics and commercial potentials. The route of administration segmentation provides valuable insights into patient compliance and therapeutic outcomes, with modalities ranging from Inhalation and Intramuscular to Intravenous, Oral, and Subcutaneous methods that reflect the complexity of patient needs and clinical practices.

Examining therapeutic areas, the market is analyzed across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. Further refinement in this area sees the Infectious Diseases category dissected into Bacterial Infections, Fungal Infections, and Viral Infections, while Oncology is analyzed through the lens of Hematologic Malignancies and Solid Tumors. Complementing this, market end-user segmentation evaluates the impact on Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies. This intricate segmentation not only informs strategic decision-making, but also provides a granular view of how patient demographics, therapy types, and regional variations coalesce to shape market trajectory.

Based on Drug Type, market is studied across Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. The RNA Interference (RNAi) Therapeutics is further studied across MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA).

Based on Molecule Type, market is studied across Large Molecule and Small Molecule.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, and Subcutaneous.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. The Infectious Diseases is further studied across Bacterial Infections, Fungal Infections, and Viral Infections. The Oncology is further studied across Hematologic Malignancies and Solid Tumors.

Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Global Regional Dynamics in Nucleic Acid-Based Drugs

Assessing the regional landscape of the nucleic acid-based drugs market provides a comprehensive perspective on global trends and regional variances. Market trends in the Americas continue to be driven by robust regulatory frameworks and extensive research infrastructure, attracting substantial investments and fostering innovation across both established markets and emerging clusters. Collaborative ecosystems with world-class research institutions and commercial players further strengthen market resilience.

In regions encompassing Europe, the Middle East & Africa, a blend of progressive regulatory reforms and increasing clinical trial activities is contributing to market expansion. This region is characterized by a harmonious blend of advanced research capabilities and strategic governmental incentives, thereby facilitating rapid clinical translations and enabling a smooth integration of breakthrough therapies into therapeutic regimens.

Meanwhile, in the Asia-Pacific region, rapid industrialization, rising healthcare demands, and a surge in technological advancements are collectively igniting market growth. Investments in infrastructure coupled with a rising focus on personalized medicine have catalyzed the development of state-of-the-art genome therapies. Each of these regions plays a significant role in influencing market strategies and expanding the global footprint of nucleic acid-based therapies, reflecting both localized opportunities and broader industry trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Strategic Company Performances and Market Leadership

In a rapidly advancing field marked by innovation and evolving therapeutic approaches, key companies have emerged as market leaders and principal drivers of growth. Prominent organizations such as Alnylam Pharmaceuticals, Inc., Amgen Inc., and Arcturus Therapeutics Holdings Inc. have spearheaded research initiatives that underscore the clinical potential of nucleic acid-based interventions. Moreover, companies like Arrowhead Pharmaceuticals, Inc. and AstraZeneca PLC have positioned themselves at the forefront of strategic collaborations and clinical advancements, further cementing their roles as industry pioneers.

The market is also notably influenced by dynamic contributions from Beam Therapeutics Inc. alongside acclaimed biopharmaceutical enterprises including Biogen, Inc. and BioMarin Pharmaceutical Inc. Furthermore, innovative players such as BioNTech SE and Bluebird Bio, Inc. are continually making strides through novel therapeutic platforms and breakthrough research. The involvement of CRISPR Therapeutics AG, CureVac N.V., and Dynavax Technologies Corporation underscores the commitment to harnessing genetic engineering techniques for therapeutic advancements.

Advancements spearheaded by Editas Medicine, Inc., Eli Lilly and Company, and Evotec SE have been pivotal in transforming market rifts into opportunities, while Generation Bio Co., Gilead Sciences, Inc., and GSK PLC continue to drive clinical research forward. With strategic insights from Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and Merck & Co., Inc., along with innovative contributions by Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., and Pfizer Inc., the competitive landscape remains both robust and dynamic. The involvement of additional influential organizations such as ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd. further exemplifies the dynamic nature of this market and its potential for continued growth and innovation.

The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amgen Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Biogen, Inc., BioMarin Pharmaceutical Inc., BioNTech SE, Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dynavax Technologies Corporation, Editas Medicine, Inc., Eli Lilly and Company, Evotec SE, F. Hoffmann-La Roche Ltd., Generation Bio Co., Gilead Sciences, Inc., GSK PLC, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., Pfizer Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd.. Actionable Strategies for Market Leadership Advancement

Industry leaders are presented with a range of actionable recommendations to navigate the complexities of the nucleic acid-based drugs market. Foremost, sustaining competitive advantage requires continuous investment in research and development, with a particular emphasis on next-generation sequencing and novel therapeutic platforms. Embracing collaborative research models will enable the pooling of expertise and resources, thereby accelerating the transition from lab-scale studies to clinical applications.

Market leaders should also focus on integrating real-world evidence and data analytics to better understand patient outcomes and refine therapeutic pipelines. Strengthening relationships with regulatory bodies and aligning with evolving global standards can expedite market entry and mitigate compliance risks. Tailored strategies that emphasize precision medicine should aim to capture patient-specific nuances while also addressing broader clinical needs.

Given the dynamic nature of market segmentation, organizations would benefit from a flexible portfolio strategy that is responsive to shifts across drug types, molecule classifications, administration routes, therapeutic areas, and end-user segments. Leveraging digital transformation tools and advanced biomanufacturing capacity will be essential in optimizing supply chains and fostering efficiency. This strategic approach can not only enhance market share but also secure long-term sustainability in the face of evolving global health challenges.

In-depth Conclusion on Market Trends and Strategies

The comprehensive analysis of the nucleic acid-based drugs market reveals a landscape defined by rapid innovation, evolving regulatory practices, and growing clinical potential. Transformations in scientific discovery and technological integration have laid the foundation for novel therapeutic solutions that address previously unmet healthcare needs. The intersection of scientific excellence and strategic market segmentation has provided stakeholders with a nuanced understanding of market dynamics, underscoring the importance of tailored strategies in both clinical and commercial domains.

This executive summary reflects a synthesis of critical insights ranging from transformative market shifts and segmentation insights to regional and corporate strategies that are collectively shaping the future of nucleic acid-based therapeutics. As scientific advancements continue to redefine therapeutic paradigms, industry players are well-advised to pursue collaborative frameworks, invest in groundbreaking research, and adapt to the evolving landscape with agility. The compelling integration of regional insights and strategic corporate insights further signifies the promising trajectory of this vibrant market, positioning it as a key driver of future success in global health innovation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of genetic disorders and chronic diseases drives the need for nucleic acid-based drugs
    • 5.1.1.2. Increasing government investments to advance nucleic acid drug manufacturing
  • 5.1.2. Restraints
    • 5.1.2.1. High manufacturing and formulation costs associated with nucleic acid-based drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Partnership and collaboration among biotech companies to enhance nucleic acid-based drugs
    • 5.1.3.2. Developing next-generation delivery systems to improve the bioavailability of nucleic acid drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Safety and delivery efficacy concerns of nucleic acid-based drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Usage of mRNA-based therapeutics due to transformative impact in vaccine development and rapid therapeutic responses during critical health crises
  • 5.2.2. Molecule Type: Widespread adoption of small molecule drugs due to their favorable properties in terms of manufacturing, administration, and cost-effectiveness
  • 5.2.3. Route of Administration: Prevalence of intramuscular injection due to its vital role in vaccine development
  • 5.2.4. Therapeutic Area: Utilization of nucleic acid-based drugs in oncology
  • 5.2.5. End-User: Widespread usage in academic & research institutes driven by need for advanced tools to unravel the intricacies of gene regulation and expression
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nucleic Acid-Based Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Antisense Oligonucleotides
• 6.3. DNA/RNA Aptamers
• 6.4. mRNA-Based Therapeutics
• 6.5. Nucleoside Analogs
• 6.6. RNA Interference (RNAi) Therapeutics
  • 6.6.1. MicroRNA (MiRNA)
  • 6.6.2. Short Hairpin RNA (ShRNA)
  • 6.6.3. Short Interfering RNA (SiRNA)

7. Nucleic Acid-Based Drugs Market, by Molecule Type

• 7.1. Introduction
• 7.2. Large Molecule
• 7.3. Small Molecule

8. Nucleic Acid-Based Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Inhalation
• 8.3. Intramuscular
• 8.4. Intravenous
• 8.5. Oral
• 8.6. Subcutaneous

9. Nucleic Acid-Based Drugs Market, by Therapeutic Area

• 9.1. Introduction
• 9.2. Cardiovascular Diseases
• 9.3. Infectious Diseases
  • 9.3.1. Bacterial Infections
  • 9.3.2. Fungal Infections
  • 9.3.3. Viral Infections
• 9.4. Metabolic Disorders
• 9.5. Neurological Disorders
• 9.6. Oncology
  • 9.6.1. Hematologic Malignancies
  • 9.6.2. Solid Tumors
• 9.7. Rare Diseases

10. Nucleic Acid-Based Drugs Market, by End-User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Contract Research Organizations
• 10.4. Hospitals & Clinics
• 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Nucleic Acid-Based Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Nucleic Acid-Based Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. SCG Cell Therapy collaborates with A*STAR BTI and NATi to fast-track RNA-based cell and gene therapy in Singapore
  • 14.3.2. FDA approves TRYNGOLZA, fueling a pipeline for nucleic acid therapies
  • 14.3.3. Singapore launches non-GMP NATi mRNA BioFoundry to enhance automated nucleic acid therapeutics research
  • 14.3.4. City Therapeutics secures USD 135 million Series A financing to revolutionize RNA interference therapies and advance next-generation RNAi engineering platform
  • 14.3.5. Evonik partners with KNAUER to expands its portfolio of biosolution
  • 14.3.6. GSK deepens its focus on nucleic acid-based treatments through the acquisition of Elsie Biotechnologies
  • 14.3.7. Aldevron and Acuitas Therapeutics join forces to accelerate next-generation cell and gene therapies
  • 14.3.8. UK invests GBP 4.5 million in advanced nucleic acid drug manufacturing
  • 14.3.9. Asahi Kasei Bioprocess and Axolabs forge a strategic Berlin partnership to build a 59,000 square foot cGMP facility for scalable oligonucleotide therapeutic production
  • 14.3.10. Evonik signs a license with the University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Pfizer Inc.
  • 14.4.2. Novo Nordisk A/S
  • 14.4.3. Moderna, Inc.
  • 14.4.4. Ionis Pharmaceuticals, Inc.

Companies Mentioned

• 1. Alnylam Pharmaceuticals, Inc.
• 2. Amgen Inc.
• 3. Arcturus Therapeutics Holdings Inc.
• 4. Arrowhead Pharmaceuticals, Inc.
• 5. AstraZeneca PLC
• 6. Beam Therapeutics Inc.
• 7. Biogen, Inc.
• 8. BioMarin Pharmaceutical Inc.
• 9. BioNTech SE
• 10. Bluebird Bio, Inc.
• 11. CRISPR Therapeutics AG
• 12. CureVac N.V.
• 13. Dynavax Technologies Corporation
• 14. Editas Medicine, Inc.
• 15. Eli Lilly and Company
• 16. Evotec SE
• 17. F. Hoffmann-La Roche Ltd.
• 18. Generation Bio Co.
• 19. Gilead Sciences, Inc.
• 20. GSK PLC
• 21. Intellia Therapeutics, Inc.
• 22. Ionis Pharmaceuticals, Inc.
• 23. Merck & Co., Inc.
• 24. Moderna, Inc.
• 25. Novartis AG
• 26. Novo Nordisk A/S
• 27. Orna Therapeutics, Inc.
• 28. Pfizer Inc.
• 29. ProQR Therapeutics N.V.
• 30. Sangamo Therapeutics, Inc.
• 31. Sanofi SA
• 32. Sarepta Therapeutics, Inc.
• 33. Silence Therapeutics PLC
• 34. Stoke Therapeutics, Inc.
• 35. Takeda Pharmaceutical Company Limited
• 36. Vertex Pharmaceuticals Incorporated
• 37. Voyager Therapeutics, Inc.
• 38. Wave Life Sciences Ltd.